Price Caps on Insulin Costs Improve Access for Medicare Beneficiaries

A recent study published in the Journal of the American Medical Association highlights the effectiveness of price caps on insulin costs for Medicare beneficiaries. The research reveals that approximately 75% of Medicare recipients could purchase a month's supply of insulin for $35 or less following the introduction of these caps. In contrast, only around 48% enjoyed such affordability in 2019, marking a substantial improvement.

The average out-of-pocket cost for insulin fell to about $22 per month in 2023, down from just over $50 in 2019. This reduction signals the broad impact of the Inflation Reduction Act of 2022, which implemented a cap on insulin costs under Medicare Part D starting January 2023. Lead researcher Michael Fang from Johns Hopkins Bloomberg School of Public Health noted the positive impact on insulin access and affordability, with costs reaching historically low levels.

The study analyzed Medicare claims data from nearly 3.8 million patients with at least one insulin prescription between 2019 and 2023, underscoring the price cap's extensive reach. However, it found that 25% of Medicare patients still paid more than $35 per month, largely due to the cap's application to full 30-day increments, resulting in higher charges when prescriptions differ. Researchers pointed out state-level cost discrepancies, with expenses ranging from just over $10 in Washington D.C. to more than $31 in Minnesota, reflecting varied implementation of federal requirements. The American Diabetes Association offers more information on state-specific insulin copay caps for further insights.